Verona Historical Balance Sheet

VRNA Stock

USD 34.98 1.05 3.09%

Trend analysis of Verona Pharma PLC balance sheet accounts such as Total Assets of 323.5 M, Total Current Liabilities of 7.7 M, Total Stockholder Equity of 261.7 M or Accounts Payable of 3.7 M provides information on Verona Pharma's total assets, liabilities, and equity, which is the actual value of Verona Pharma PLC to its prevalent stockholders. By breaking down trends over time using Verona Pharma balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Verona Pharma PLC latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Verona Pharma PLC is a good buy for the upcoming year.

Verona Pharma Inventory

0.95

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

About Verona Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Verona Pharma PLC at a specified time, usually calculated after every quarter, six months, or one year. Verona Pharma Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Verona Pharma and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Verona currently owns. An asset can also be divided into two categories, current and non-current.

Verona Pharma Balance Sheet Chart

At present, Verona Pharma's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Total Stockholder Equity is expected to grow to about 261.7 M, whereas Total Current Liabilities is forecasted to decline to about 7.7 M.

Total Assets Total Current Liabilities Total Stockholder Equity Accounts Payable

Add Fundamental

Total Assets

Total assets refers to the total amount of Verona Pharma assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Verona Pharma PLC books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Verona Pharma balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Verona Pharma PLC are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Total Stockholder Equity

The total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders.

Accounts Payable

An accounting item on the balance sheet that represents Verona Pharma obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Verona Pharma PLC are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most accounts from Verona Pharma's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Verona Pharma PLC current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Verona Pharma PLC. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.

	2021	2022	2023	2024 (projected)
Total Current Liabilities	33.4M	19.0M	8.7M	7.7M
Total Assets	186.6M	259.5M	308.1M	323.5M

Total Current Liabilities Total Assets

Verona Pharma balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Inventory	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Current Liab	Property Plant And Equipment Net	Good Will	Short Term Investments	Property Plant And Equipment Gross	Intangible Assets	Net Tangible Assets
Total Assets		0.54	1.0	-0.97	-0.97	0.51	0.98	0.86	0.92	0.33	1.0	0.79	-0.42	0.33	0.78	0.99	0.94	1.0	0.98	0.32	0.86	-0.76	0.26	0.9	0.88	1.0
Total Current Liabilities	0.54		0.54	-0.55	-0.55	0.81	0.47	0.51	0.61	0.3	0.51	0.78	-0.21	0.71	0.26	0.54	0.5	0.53	0.55	0.43	0.26	-0.76	0.28	0.23	0.72	0.53
Total Stockholder Equity	1.0	0.54		-0.97	-0.96	0.48	0.98	0.83	0.93	0.35	1.0	0.78	-0.43	0.35	0.77	0.99	0.91	1.0	0.98	0.34	0.83	-0.75	0.27	0.87	0.87	0.99
Net Debt	-0.97	-0.55	-0.97		0.96	-0.46	-0.99	-0.83	-0.97	-0.36	-0.97	-0.74	0.36	-0.44	-0.66	-0.97	-0.88	-0.97	-0.99	-0.28	-0.82	0.69	-0.07	-0.87	-0.83	-0.98
Retained Earnings	-0.97	-0.55	-0.96	0.96		-0.58	-0.97	-0.92	-0.94	-0.29	-0.96	-0.84	0.45	-0.41	-0.67	-0.99	-0.94	-0.96	-0.98	-0.28	-0.89	0.7	-0.11	-0.89	-0.86	-0.98
Accounts Payable	0.51	0.81	0.48	-0.46	-0.58		0.45	0.7	0.57	0.07	0.47	0.81	-0.27	0.4	0.32	0.54	0.62	0.5	0.54	0.07	0.38	-0.52	0.22	0.39	0.56	0.51
Cash	0.98	0.47	0.98	-0.99	-0.97	0.45		0.86	0.95	0.32	0.98	0.73	-0.36	0.34	0.71	0.98	0.92	0.98	0.99	0.24	0.88	-0.66	0.07	0.93	0.82	0.99
Non Current Assets Total	0.86	0.51	0.83	-0.83	-0.92	0.7	0.86		0.82	0.05	0.84	0.77	-0.36	0.22	0.64	0.9	0.91	0.84	0.88	0.21	0.81	-0.55	0.03	0.83	0.71	0.87
Non Currrent Assets Other	0.92	0.61	0.93	-0.97	-0.94	0.57	0.95	0.82		0.39	0.92	0.8	-0.4	0.55	0.55	0.94	0.85	0.92	0.98	0.15	0.79	-0.63	0.01	0.83	0.79	0.95
Other Assets	0.33	0.3	0.35	-0.36	-0.29	0.07	0.32	0.05	0.39		0.33	0.33	0.03	0.44	0.16	0.31	0.2	0.34	0.33	0.13	0.21	-0.49	0.09	0.21	0.41	0.33
Cash And Short Term Investments	1.0	0.51	1.0	-0.97	-0.96	0.47	0.98	0.84	0.92	0.33		0.76	-0.42	0.31	0.79	0.99	0.93	1.0	0.97	0.32	0.85	-0.75	0.27	0.9	0.87	0.99
Net Receivables	0.79	0.78	0.78	-0.74	-0.84	0.81	0.73	0.77	0.8	0.33	0.76		-0.45	0.61	0.52	0.81	0.8	0.78	0.8	0.26	0.71	-0.77	0.29	0.64	0.87	0.79
Common Stock Shares Outstanding	-0.42	-0.21	-0.43	0.36	0.45	-0.27	-0.36	-0.36	-0.4	0.03	-0.42	-0.45		-0.37	-0.15	-0.44	-0.34	-0.42	-0.44	0.08	-0.41	0.19	-0.36	-0.35	-0.37	-0.43
Inventory	0.33	0.71	0.35	-0.44	-0.41	0.4	0.34	0.22	0.55	0.44	0.31	0.61	-0.37		-0.16	0.36	0.22	0.34	0.43	0.16	0.24	-0.47	-0.08	0.11	0.53	0.37
Other Current Assets	0.78	0.26	0.77	-0.66	-0.67	0.32	0.71	0.64	0.55	0.16	0.79	0.52	-0.15	-0.16		0.73	0.78	0.78	0.66	0.31	0.65	-0.62	0.5	0.73	0.65	0.74
Other Stockholder Equity	0.99	0.54	0.99	-0.97	-0.99	0.54	0.98	0.9	0.94	0.31	0.99	0.81	-0.44	0.36	0.73		0.95	0.99	0.99	0.3	0.88	-0.72	0.19	0.9	0.87	1.0
Total Liab	0.94	0.5	0.91	-0.88	-0.94	0.62	0.92	0.91	0.85	0.2	0.93	0.8	-0.34	0.22	0.78	0.95		0.93	0.91	0.23	0.92	-0.72	0.18	0.94	0.85	0.93
Total Current Assets	1.0	0.53	1.0	-0.97	-0.96	0.5	0.98	0.84	0.92	0.34	1.0	0.78	-0.42	0.34	0.78	0.99	0.93		0.97	0.33	0.85	-0.76	0.27	0.89	0.88	0.99
Common Stock	0.98	0.55	0.98	-0.99	-0.98	0.54	0.99	0.88	0.98	0.33	0.97	0.8	-0.44	0.43	0.66	0.99	0.91	0.97		0.23	0.85	-0.67	0.09	0.89	0.83	0.99
Other Current Liab	0.32	0.43	0.34	-0.28	-0.28	0.07	0.24	0.21	0.15	0.13	0.32	0.26	0.08	0.16	0.31	0.3	0.23	0.33	0.23		0.09	-0.67	0.39	0.0	0.54	0.27
Property Plant And Equipment Net	0.86	0.26	0.83	-0.82	-0.89	0.38	0.88	0.81	0.79	0.21	0.85	0.71	-0.41	0.24	0.65	0.88	0.92	0.85	0.85	0.09		-0.56	0.01	0.95	0.77	0.86
Good Will	-0.76	-0.76	-0.75	0.69	0.7	-0.52	-0.66	-0.55	-0.63	-0.49	-0.75	-0.77	0.19	-0.47	-0.62	-0.72	-0.72	-0.76	-0.67	-0.67	-0.56		-0.5	-0.5	-0.95	-0.71
Short Term Investments	0.26	0.28	0.27	-0.07	-0.11	0.22	0.07	0.03	0.01	0.09	0.27	0.29	-0.36	-0.08	0.5	0.19	0.18	0.27	0.09	0.39	0.01	-0.5		0.02	0.39	0.19
Property Plant And Equipment Gross	0.9	0.23	0.87	-0.87	-0.89	0.39	0.93	0.83	0.83	0.21	0.9	0.64	-0.35	0.11	0.73	0.9	0.94	0.89	0.89	0.0	0.95	-0.5	0.02		0.69	0.9
Intangible Assets	0.88	0.72	0.87	-0.83	-0.86	0.56	0.82	0.71	0.79	0.41	0.87	0.87	-0.37	0.53	0.65	0.87	0.85	0.88	0.83	0.54	0.77	-0.95	0.39	0.69		0.86
Net Tangible Assets	1.0	0.53	0.99	-0.98	-0.98	0.51	0.99	0.87	0.95	0.33	0.99	0.79	-0.43	0.37	0.74	1.0	0.93	0.99	0.99	0.27	0.86	-0.71	0.19	0.9	0.86

Click cells to compare fundamentals

Verona Pharma Account Relationship Matchups

Verona Pharma balance sheet Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	59.2M	204.2M	186.6M	259.5M	308.1M	323.5M
Total Current Liabilities	12.6M	14.2M	33.4M	19.0M	8.7M	7.7M
Total Stockholder Equity	44.4M	184.9M	148.0M	230.5M	249.3M	261.7M
Net Debt	(28.8M)	(182.0M)	(142.6M)	(217.2M)	(220.4M)	(209.4M)
Retained Earnings	(131.9M)	(207.1M)	(263.7M)	(333.1M)	(388.4M)	(369.0M)
Accounts Payable	1.9M	178K	10.0M	2.9M	3.5M	3.7M
Cash	30.1M	188.0M	148.4M	227.8M	271.8M	285.4M
Non Current Assets Total	5.5M	1.7M	16.5M	16.5M	18.4M	19.3M
Cash And Short Term Investments	40.3M	188.0M	148.4M	227.8M	271.8M	285.4M
Net Receivables	9.8M	8.3M	15.6M	9.3M	11.0M	11.5M
Common Stock Shares Outstanding	13.2M	32.9M	59.1M	66.1M	79.3M	75.3M
Liabilities And Stockholders Equity	59.2M	204.2M	186.6M	259.5M	308.1M	323.5M
Inventory	3.5M	4.5M	4.0M	2.5M	1.0	0.95
Other Current Assets	10.2K	1.7M	2.1M	3.4M	7.0M	7.3M
Other Stockholder Equity	158.0M	364.7M	384.5M	527.6M	599.5M	629.5M
Total Liab	14.8M	19.4M	38.6M	29.0M	58.8M	61.8M
Total Current Assets	53.7M	202.5M	170.1M	243.0M	289.7M	304.2M
Common Stock	6.9M	31.8M	31.9M	40.5M	42.8M	44.9M
Other Current Liab	10.1M	2.4M	327K	15.4M	4.0M	3.9M
Property Plant And Equipment Net	1.3M	1.2M	979K	927K	2.9M	3.0M
Good Will	596.0K	559.6K	578.2K	545K	490.5K	466.0K
Short Term Investments	66.0M	57.0M	10.3M	10.3M	11.8M	20.1M
Property Plant And Equipment Gross	43K	1.2M	979K	927K	2.9M	3.0M
Net Tangible Assets	42.2M	184.3M	167.7M	229.9M	264.4M	277.6M
Property Plant Equipment	1.4M	1.2M	979K	927K	1.1M	1.1M
Short Term Debt	603.1K	798K	648K	675K	1.2M	606.4K
Non Current Liabilities Total	2.2M	5.1M	5.2M	10.0M	50.1M	52.7M
Capital Lease Obligations	951K	1.3M	934K	880K	3.0M	3.1M
Short Long Term Debt Total	1.2M	5.9M	5.8M	10.6M	51.3M	53.9M
Current Deferred Revenue	0.0	10.9M	22.4M	1.0	1.15	1.09
Net Invested Capital	44.4M	189.5M	152.9M	240.2M	297.7M	174.8M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

V	Visa Class A
F	Ford Motor
CSL	Carlisle Companies Incorporated

When determining whether Verona Pharma PLC offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Verona Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Verona Pharma Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Verona Pharma Plc Stock:

How To Invest In Verona

Details

Is Verona Stock a good investment?

Details

What is Verona Pharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

You can also try the FinTech Suite module to use AI to screen and filter profitable investment opportunities.

Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verona Pharma. If investors know Verona will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verona Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(1.60)

Revenue Per Share

0.006

Return On Assets

(0.22)

Return On Equity

(0.57)

The market value of Verona Pharma PLC is measured differently than its book value, which is the value of Verona that is recorded on the company's balance sheet. Investors also form their own opinion of Verona Pharma's value that differs from its market value or its book value, called intrinsic value, which is Verona Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verona Pharma's market value can be influenced by many factors that don't directly affect Verona Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Verona Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Verona Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verona Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Verona Historical Balance Sheet

Verona Pharma Inventory

0.95

About Verona Balance Sheet Analysis

Verona Pharma Balance Sheet Chart

Total Assets

Total Current Liabilities

Total Stockholder Equity

Accounts Payable

Verona Pharma balance sheet Correlations

Verona Pharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Verona Pharma balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Stockholder Equity	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Net Tangible Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Stockholder Equity
Total Current Assets	+ 1.0	Total Stockholder Equity

Other Stockholder Equity	- 0.99	Retained Earnings
Common Stock	- 0.99	Net Debt
Cash	- 0.99	Net Debt
Net Tangible Assets	- 0.98	Retained Earnings
Common Stock	- 0.98	Retained Earnings
Net Tangible Assets	- 0.98	Net Debt